Under valued stock, page-80

Hi Titans,

A quick reply (more time to read up on this tomorrow).
I think there is every possibility that the drugs could complement each other & be indicated for various stages of AD & prevention of cognitive decline. I’m not a pharmacologist. The drugs work in different ways.

Dr G is trained in Pharmacology, so maybe you could drop him an email & ask his thoughts on the topic if you get time today? I would be interested to hear also.

Xanamem will have to go through the regulatory steps & clinical trial stages, including Ph3. AD & neuro-degenerative diseases have been a very difficult space, but we are seeing things move forward.

Another thing to think about is access & equity issues to high cost drugs. AD is classified by WHO as a global priority & endemic. $US56,000 pa infusions are not going to be available to everyone who it may help & there are risks with safety (cerebral oedema), but we are talking about a slow decline in a terminal disease here.

Xanamem has been shown to be safe & oral route, so that’s a bonus!

GLTAH